J&J Submits Ceftobiprole NDA
This article was originally published in The Pink Sheet Daily
Executive Summary
Novel cephalosporin would be used to treat complicated skin and skin structure infections, including diabetic foot infections.
You may also be interested in...
FDA Wants More Ceftobiprole Data From J&J/Basilea
Racing against Theravance's "approvable" telavancin, company will supply added results in diabetic foot infections.
FDA Wants More Ceftobiprole Data From J&J/Basilea
Racing against Theravance's "approvable" telavancin, company will supply added results in diabetic foot infections.
FDA Anti-Infective Drugs Advisory Committee To Review Two Antibiotics
Johnson & Johnson’s ceftobiprole and Theravance’s telavancin will be discussed Feb. 27-28.